Eicosanoids and inflammation
1988; Volume: 156; Issue: 2 Linguagem: Inglês
10.1002/path.1711560204
ISSN1096-9896
Autores Tópico(s)Fatty Acid Research and Health
ResumoThe Journal of PathologyVolume 156, Issue 2 p. 101-110 Review Article Eicosanoids and inflammation Dr. K. I. Williams, Corresponding Author Dr. K. I. Williams School of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, U.K.School of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, U.K.Search for more papers by this authorG. A. Higgs, G. A. Higgs Department of Pharmacology, Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, U.K.Search for more papers by this author Dr. K. I. Williams, Corresponding Author Dr. K. I. Williams School of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, U.K.School of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, U.K.Search for more papers by this authorG. A. Higgs, G. A. Higgs Department of Pharmacology, Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, U.K.Search for more papers by this author First published: October 1988 https://doi.org/10.1002/path.1711560204Citations: 83AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Piper P, Vane JR. The release of prostaglandins from the lungs and other tissues. Ann. NY Acad Sci 1971; 180: 363–385. 2 Rahman YE, Wiel JV. Evidence of a membrane bound phospholipase A in rat liver microsomes. Biochem Biophys Res Commun 1970; 38: 670–677. 3 Pickett WC, Jesse RL, Cohen P. Initiation of phospholipase A2 activity in human platelets by the calcium ionophore A23 187. Biochim Biophys Acta 1977; 486: 209–213. 4 Kunze H, Vogt W. Significance of phospholipase A for prostaglandin formation. Ann NY Acad Sci 197 180: 123–125. 5 Newkirk D, Waite M. Phospholipid hydrolysis by phospholipases A1 and A2 in plasma membranes and microsomes of rat liver. Biochim Biophys Acta 1973; 298: 562–576. 6 Vargaftig BB, Dao Hai N. Selective inhibition by mepacrine of the release of "rabbit aorta contracting substance" evoked by administration of bradykinin. J Pharm Pharmacol 1972; 24: 159–161. 7 Mitchell S, Poyser NL, Wilson NH. Effect of p-bromophenacyl bromide, an inhibitor of phospholipase A2, on arachidonic acid release and prostaglandin synthesis by the guinea pig uterus in vitro. Br J. Pharmacol 1977; 59: 107–114. 8 Blackwell GJ, Carnuccio R, Di Rosa RM, et al. Macrocortin: a polypeptide causing the antiphospholipase effect of glucocorticoids. Nature 1981; 287: 147–149. 9 Hirata F, Schiffman E, Venkatasubramanian K, et al. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acd Sci USA 1980; 77: 2533–2536. 10 Vane JR. Inhibition of prostaglandin synthesis as a possible mechanism of action for the aspirin-like drugs. Nature 1971; 231: 232–235. 11 Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073–3076. 12 Hamberg M, Svensson J, Sammuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994–2998. 13 Blackwell GJ, Flower RJ, Russell-Smith N, et al. In-butyl-imidazole: a potent and selective inhibitor of thromboxane synthetase. Br J Phamacol 1978; 64: 435P. 14 Tyler HM, Saxton D, Parry MJ. Administration to man of UK-37248-01, a selective inhibitor of thromboxane synthetase. Lancet 1981; 1: 629–632. 15 Moncada S, Gryglewski RJ, Bunting S et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663–665. 16 Moncada S, Gryglewski RJ, Bunting S, et al. A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins 1976; 12: 715–733. 17 Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions of inflammation. Science 1983; 220: 568–575. 18 Borgeat P, Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc Natl Acad Sci USA 1979; 76: 3213–3217. 19 Smith MJH, Ford-Hutchison AW, Bray MA. Leukotriene B: a potential mediator of inflammation. J Pharm Pharmacol 1979; 32: 517–518. 20 Palmblad J, Malmsten CL, Uden AM, et al. Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood 1981; 58: 658–661. 21 Lewis RA, Austen KF, Drazen JM, et al. Slow reacting substances of anaphylaxis: Identification of leukotrienes C and D from human and rat sources. Proc Natl Acad Sci USA 1980; 77: 3710–3714. 22 Ahern DG, Downing DT. Inhibition of prostaglandin biosynthesis by eicosa-5, 8, 11, 14-tetraynoic acid. Biochim Biophys Acta 1970; 210: 456–461. 23 Higgs GA, Flower RJ, Vane JR. A new approach to anti-inflammatory drugs. Biochem Pharmacol 1979; 28: 1959–1961. 24 Bray M. Retinoids are potent inhibitors of the generation of rat leukocyte leukotriene B4-like activity in vitro. Eur J Pharmacol 1984; 98: 61–67. 25 Bhattacherjee P, Follengant RL, Garland LG, et al. The pharmacological properties of a novel series of selective inhibitors of arachidonate 5-lipoxygenase. In: MJ Rand, C Raper, eds. Pharmacology. Amsterdam: Elsevier, 1987; 333–336. 26 Capdevila J, Chacos N, Werringloer J, et al. Liver microsomal cytochrome P450 and the oxidative metabolism of arachidonic acid. Proc Natl Acad Sci USA 1981; 78: 5362–5366. 27 Proctor KG, Falck JR, Capdevila J. Intestinal vasodilation by epoxyeicosatrienoic acids: arachidonic acid metabolites produced by a cytochrome P450 mono-oxygenase. Circ Res 1987; 60: 50–59. 28 Serhan CN, Hamberg M, Samuelsson B. Lipoxins: a novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 1984; 81: 5335–5339. 29 Moncada S. Prostacyclin, thromboxane and leukotrienes. Br Med Bull 1983; 39: 209–298. 30 Gerrard JM. Prostaglandins and Leukotrienes: Blood and Vascular cell function. New York: Marcel Dekker, 1985. 31 Willis AL. Release of histamine, kinin and prostaglandins during carrageenin-induced inflammation of the rat. In: P Mantegazza, EW Horton, eds. Prostaglandins, Peptides and Amines. London: Academic Press, 1969; 33–38. 32 Bonta IL, Parnham MJP. Reduced exudation and increased tissue proliferation during chronic inflammation in rats deprived of endogenous prostaglandin precursors. Prostaglandins 1977; 14: 295–307. 33 Herman AG, Moncada S. Release of prostaglandins and incapacitation after injection of endotoxin in the knee joint of the dog. Br J Pharmacol 1975; 53: 465P. 34 Glatt M, Peskar B, Brune K. Leukocytes and prostaglandins in acute inflammation. Experientia 1974; 30: 1257–1259. 35 Arhut H, Brune K, Frolich JC, et al. Prostaglandin D2 is the prevailing prostaglandin in the acute inflammatory exudate of urate arthritis in chicken. Br J Pharmacol 1979; 65: 357–359. 36 Hammarstrom S, Hamberg M, Samuelsson B, et al. Increased concentrations of non-esterified arachidonic acid, 12L-hydroxy-5, 8, 10, 14-eicostatetraenoic acid, prostaglandin E2 and prostaglandin F2 a in epidermis of psoriasis. Proc Natl Acad Sci USA 1975; 82: 5130–5134. 37 Brain SD, Camp RDR, Dowd PM, et al. Psoriasis and leukotriene B4. Lancet 1982; ii: 762–763. 38 Austen, KF. Homeostasis of effector systems which can also be recruited for immunological reactions. J Immunol 1978; 121: 793–805. 39 Koshihara Y, Nagasaki I, Muorta S-I. Production of slow reacting substance in rat granulomatous inflammation. Biochem Pharmacol 1981; 30: 1781–1784. 40 Simmons PM, Salmon JA, Moncada S. The release of leukotriene B4 during experimental inflammation. Biochem Pharmacol 1983; 32: 1353–1359. 41 Haworth D, Carey F. Identification of immunoreactive LTB4 in the yeast inflamed rat paw. In: GA Higgs, TJ Williams, eds. Inflammatory Mediators. London: Macmillan, 1985; 37–45. 42 Chang WC, Murota SI, Tsurufuji S. Thromboxane B2 transformed from arachidonic acid in carrageenin-induced granuloma. Prostaglandins 1977; 13: 12–24. 43 Chang WC, Murota SI, Matsuo M, et al. A new prostaglandin transformed from arachidonic acid in carrageenin-induced granuloma. Biochem Biophys Res Commun 1976; 72: 1259–1264. 44 Robinson DR, Smith H, McGuire MB, et al. Prostaglandin synthesis by rheumatoid synovium and its stimulation by colchicine. Prostaglandins 1975; 10: 67–85. 45 Sturge RA, Yates DB, Gordon D, et al. Prostaglandin production in arthritis. Ann Rheum Dis 1978; 37: 315–320. 46 Salmon JA, Higgs GA, Vane JR, et al. Synthesis of arachidonic cyclo-oxygenase products by rheumatoid and non-rheumatoid synovial lining in non-proliferative organ culture. Ann Rheum Dis 1983; 42: 36–39. 47 Blotman F, Chaintreul J, Poubelle P, et al. PGE2, PGF2a and TXB2 biosynthesis by human rheumatoid synovia. In: B Samuelsson, PW Ramwell, R Paoletti, eds. Advances in Prostaglandin and Thromboxane Research. New York: Raven Press, 1980; 8: 1705–1708. 48 Chaintreuil J, Blotman F, Flandre O, et al. Prostaglandin biosynthesis by normal and rheumatoid synovial tissue: a comparative study on microsomes and whole homogenates. Eur J Rheumatol 1979; 2: 119–121. 49 Dumonde DC, Glynn LE. The production of arthritis in rabbits by an immunological reaction to fibrin. Br J Exp Pathol 1962; 43: 373–383. 50 Blackham A, Farmer JB, Radziwonik H, et al. The role of prostaglandins in rabbit monoarticular arthritis. Br J Pharmacol 1974; 51: 35–44. 51 Henderson B, Higgs GA, Moncada S, et al. Synthesis of eicosanoids by tissues of the synovial joint during the development of chronic erosive synovitis. Agents Actions 1985; 17: 360–362. 52 Higgs GA, Vane JR, Hart FD, et al. Effects of anti-inflammatory drugs on prostaglandins in rheumatoid arthritis. In: JH Robinson, JR Vane, eds. Prostaglandin Synthetase Inhibitors. New York: Raven Press, 1974; 165–173. 53 Robinson DR, Levine L. Prostaglandin concentrations in synovial fluid in rheumatic diseases: action of indomethacin and aspirin. In: JH Robinson, JR Vane, eds. Prostaglandin Synthetase Inhibitors. New York: Raven Press, 1974; 223–228. 54 Trang LE, Granstrom E, Lovgren O. Levels of prostaglandins F2 a and E2 and thromboxane B2 in joint fluid in rheumatoid arthritis. Scand J Rheumatol 1977; 6: 151–154. 55 Brodie MJ, Hensby CN, Parke A, et al. Is prostacyclin the major pro-inflammatory prostanoid in joint fluid? Life Sci 1980; 27: 603–608. 56 Tokunaga M, Ohuchi K, Yoshizawa S, et al. Change of prostaglandin E level in joint fluids after treatment with flurbiprofen in patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1981; 40: 462–465. 57 Klickstein LB, Shapleigh C, Goetzl EJ. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthitis. J Clin Invest 1980; 66: 1166–1170. 58 Davidson EM, Rae SA, Smith MJH. Leukotriene B4 in synovial fluid. J Pharm Pharmacol 1982; 34: 410. 59 Rae SA, Davidson EM, Smith MJH. Leukotriene B4, an inflammatory mediator in gout. Lancet 1982; ii: 1122–1124. 60 Bombardieri S, Cattani P, Ciabattoni G, et al. The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of steroidal and non-steroidal anti-inflammatory drugs. Br J Phamacol 1981; 73: 893–901. 61 Greaves MW, Sondergaard J, McDonald-Gibson W. Recovery of prostaglandins in human cutaneous inflammation. Br Med J 1971; ii: 258–260. 62 Goldyne ME, Winkelmann RK, Ryan RJ. Prostaglandin activity in human cutaneous inflammation: detection by radioimmunoassay. Prostaglandins 1973; 4: 737–749. 63 Higgs GA, Moncada S, Salmon JA, et al. The source of prostaglandins and thromoboxane in experimental inflammation. Br J Pharmacol 1983; 79: 863–868. 64 Salmon JA, Simmons PM, Moncada S. The effects of BW755C and other anti-inflammatory drugs on eicosanoid concentrations and leukocyte accumulation in experimentally-induced inflammation. J Pharm Pharmacol 1983; 35: 808–813. 65 Kaley G, Weiner R. Microcirculatory studies with prostaglandin E1. In: PW Ramwell, JE Shaw, eds. Prostaglandin Symposium, Worcester Foundation for Experimental Biology, New York: Wiley, 1968; 321–328. 66 Solomon LM, Juhlin L, Kirschenbaum MB. Prostaglandins on cutaneous vasculature. J Invest Dermatol 1968; 51: 280–282. 67 Juhlin L, Michaelsson G. Cutaneous vascular reactions to prostaglandins in healthy subjects and in patients with urtricaria and atopic dermatitis. Acta Derm Venereol 1969; 49: 251–261. 68 Johnston MG, Hay JB, Movat HZ. The modulation of enhanced vascular permeability by prostaglandins through alterations in blood flow (hyperemia). Agents Actions 1976; 6: 705–711. 69 Williams TJ, Peck MJ. Role of prostaglandin-mediated vasodilatation in inflammation. Nature 1977; 270: 530–532. 70 Williams TJ. Prostaglandin E2, prostaglandin I2 and the vascular changes of inflammation. Br J Pharmacol 1979; 65: 517–524. 71 Williams TJ, Morley J. Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature 1973; 246: 215–217. 72 Ikeda K, Tanaka K, Katori M. Potentiation of bradykinin-induced vascular permeability increase by prostaglandin E2 and arachidonic acid in rabbit skin. Prostaglandins 1975; 10: 747–758. 73 Wedmore CV, Williams TJ. Control of vascular permeability by polymorphonculear leukocytes in inflammation. Nature 1981; 289: 646–650. 74 Moncada S, Ferreira SH, Vane JR. Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature 1973; 246: 217–219. 75 Komoriya K, Ohmori H, Azuma A, et al. Prostaglandin I2 as a potentiator of acute inflammation in rats. Prostaglandins 1978; 15: 557–564. 76 Lewis AJ, Nelson DJ, Sugrue MF. On the ability of prostaglandin E1 and arachidonic acid to modulate experimentally-induced oedema in the rat paw. Br J Pharmacol 1975; 55: 51–56. 77 Higgs EA, Moncada S, Vane JR. Inflammatory effects of prostacyclin (PGl2) and 6-oxo-PGF1 a in the rat paw. Prostaglandins 1978; 16: 153–162. 78 Ferreira SH. Prostaglandins, aspirin-like drugs and analgesia. Nature 1972; 240: 200–203. 79 Williams TJ, Piper PJ. The action of chemically pure SRS-A on the microcirculation in vivo, Prostaglandins 1980; 19: 779–789. 80 Peck MJ, Piper PJ, Williams TJ. The effect of leukotrienes C4 and D4 on the microvasculature of guinea pig skin. Prostaglandins 1981; 21: 315–321. 81 Dahlen SE, Bjork J, Hedqvist P, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 1981; 78: 3887–3891. 82 Bray MA, Cunningham FM, Ford-Hutchinson AW, et al. Leukotriene B4: a mediator of vascular permeability. Br J Pharmacol 1981; 72: 483–486. 83 Brocklehurst WE. Properties which distinguish SRS-A from bradykinin. International Symposium on Vasoactive Polypeptides: Bradykinin and Related Polypeptides. Oxford: Pergamon, 1976; 189–191. 84 Orange RP, Austen FK. Slow reacting substance of anaphylaxis. Adv Immunol 1969; 10: 105–144. 85 Patterson R, Orange R, Harris BS. A study of the effect of slow reacting substances of anaphylaxis on the rhesus monkey airway. J Allergy Clin Immunol 1978; 62: 371–377. 86 Ueno A, Tanaka K, Katori M, et al. Species difference in increased vascular permeability by synthetic leukotrienes C4 and D4. Prostaglandins 1981; 21: 637–648. 87 Sugio K, Ohuchi K, Sugata M, et al. Suppression by dexamethasone of vascular permeability response induced with leukotrienes C and D in the rat skin. Prostaglandins 1981; 21: 649–653. 88 Higgs GA, Salmon JA, Spayne JA. The inflammatory effects of hydroperoxy- and hydroxy-acid products of arachidonate lipoxygenase in rabbit skin. Br J Pharmacol 1981; 74: 429–433. 89 Bjork J, Hedqvist P, Arfors K-E. Increase in vascular permeability induced by leukotriene B4 and the role of polymorphonuclear leukocytes. Inflammation 1982; 6: 189–200. 90 Lewis RA, Austen KF, Drazen JM, et al. Structure, function and metabolism of leukotriene constituents of SRS-A. In: B Samuelsson, R Paoletti, eds. Advances in Prostaglandin, Thromboxane and Leukotriene Research. New York: Raven Press, 1982; 137–151. 91 Bevegard S, Oro L. Effect of prostaglandin E1 on forearm blood flow. Scand J Clin Lab Invest 1969; 23: 347–352. 92 Karim SMM. Action of prostaglandin in the pregnant woman. Ann NY Acad Sci 1971; 180: 483–498. 93 Collier JC, Karim SMM, Robinson B, et al. Action of prostaglandins A2, B1, E2 and F2w a on superficial hand veins of man. Br J Pharmacol 1972; 44: 374–375. 94 Gillespie A. Prostaglandin–oxytocin enhancement and potentiation and their clinical applications. Br Med J 1972; i: 150–152. 95 Ferreira SH, Nakamura M, Abreu-Castro MS. The hyperalgesic effects of prostacyclin and PGE2. Prostaglandins 1978; 16: 31–37. 96 Levine JD, Lau W, Kwiat G, et al. Leukotriene B4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science 1984; 225: 743–745. 97 Levine JD, Lam D, Taino YD, et al. Hyperalgesic properties of 15-lipoxygenase products of arachidonic acid. Proc Natl Acad Sci 1986; 83: 5331–5334. 98 Schweizer A, Brom R, Glatt M, et al. Leukotrienes reduce nociceptive responses to bradykinin. Eur J Pharmacol 1984; 105: 105–112. 99 Gazelius B, Panpopoulus P, Odlander B, et al. Inhibition of intradental nerve excitation by leukotriene B4 and C4. Acta Physiol Scand 1984; 120: 141–143. 100 Saxena PN, Beg MMA, Singhal KC, et al. Prostaglandin-like activity in the cerebrospinal fluid of febrile patients. Indian J Med Res 1979; 70: 495–498. 101 Bernheim HA, Gilbert TM, Stitt JT. Prostaglandin E levels in third ventricular cerebrospinal fluid of rabbits during fever and changes in body temperature. J Physiol 1980; 301: 69–78. 102 Walker JR, Smith MJH, Ford-Hutchinson AW. Anti-inflammatory drugs, prostaglandins and leukocyte migration. Agents Actions 1976; 6: 602–606. 103 Rivkin I, Rosenblatt J, Becker EL. The role of cyclic AMP in the chemotactic responsiveness and spontaneous motility of rabbit peritoneal neutrophils. J Immunol 1974; 115: 1126–1134. 104 Higgs GA. Prostaglandins and the microcirculation. In: AG Herman, PM Vanhoutte, H Denolin, A Goossens eds. Cardiovascular Pharmacology of the Prostaglandins. New York: Raven Press, 1982; 315–325. 105 Boxer LA, Allen JM, Schmidt M, et al. Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. J Lab Clin Med 1980; 95: 672–678. 106 Pearson JD, Carleton JS, Beesley JE, et al. Granulocyte adhesion to enothelium in culture. J Cell Sci 1979; 38: 225–235. 107 Turner SR, Tainer JA, Lynn WS. Biogenesis of chemotactic molecules by the arachidonate lipoxygenase system of platelets. Nature 1975; 257: 680–681. 108 Ford Hutchinson AW, Bray MA, Doig MV, et al. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286: 264–265. 109 Palmer RJ, Stepney R, Higgs GA, et al. Chemokinetic activity of arachidonic acid lipoxygenase products on leukocytes from different species. Prostaglandins 1980; 20: 411–418. 110 Goetzl EJ, Pickett WC. The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs). J Immunol 1980; 125: 1789–1791. 111 Brain SD, Camp RD, Greaves MW, et al. The inflammatory response of human skin to topical application of leukotriene B4. Br J Clin Pharmacol 1984; 17: 610P–611P. 112 Bhattacherjee P, Hammond B, Salmon JA, et al. Chemotactic response to some arachidonic acid lipoxygenase products in the rabbit eye. Eur J Pharmacol 1981; 73: 21–28. 113 Higgs GA, Moncada S, Vane JR. Eicosanoids in inflammation. Ann Clin Res 1984; 16: 287–299. Citing Literature Volume156, Issue2October 1988Pages 101-110 ReferencesRelatedInformation
Referência(s)